Myeloma Crowd Round Table Expert Videos: Scottsdale -- October 14, 2018
Minimal Residual Disease Test Gets Medicare Coverage Approval for Myeloma Patients
Clinical Trial: GVAX Vaccine with Revlimid To Extend Remission
Activating the Immune System to Eat Cancer Cells
ASH 2018: One Myeloma Transplant vs. Two? That is the Question
VERY Early Detection of Multiple Myeloma
Myeloma Progress in 2018 and a Look to the Future in Multiple Myeloma with Dr. Robert Z. Orlowski, MD Anderson Cancer Center
Myeloma expert Dr. Robert Orlowski of the MD Anderson Cancer Center shares his top 18 abstracts of 2018
A New, Cheaper and More Useful Test to Detect Multiple Myeloma?
Clinical Trial: Isatuximab with RVD for Newly Diagnosed Myeloma Patients
Clinical Trial: Testing a BCMA Monoclonal Antibody (SEA-BCMA) With a T Cell Therapy (ACTR087) for Relapsed or Refractory Multiple Myeloma Patients
Neuropathy: Myeloma Patient Lou Johnson Shares Her Story
Which Multiple Myeloma Patients May Do Well with the Measles Vaccine?
Clinical Trial: Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Personalized Myeloma Treatment Using 3D Tumor Modeling
Dr. Rodriguez is using a new 3D organoid tumor modeling platform which allows the testing of over 50 myeloma treatment combinations
Perspectives from Tom Brokaw: From NBC to ASH
ASH 2018: Best Kept Secret at ASH in Multiple Myeloma
Identifying and Killing Myeloma Cells That Cause Myeloma and Relapse with MCRI Award Winner Dr. Frank Zhan and Dr. Yogesh Jethava
If patients were able to receive full myeloma therapy including therapy that could kill initiating cells, we would be much closer to a cure.
Clinical Trial: The MyDrug MMRF Study Recruiting for 228 Myeloma Patients
Day 1 of Myeloma Giving: I Don't Have Melanoma, I Have Multiple Myeloma
ASH 2018: Adding Daratumumab to Velcade/Revlimid/Dex Effective for Newly Diagnosed Multiple Myeloma
ASH 2018: Ixazomib and Elotuzumab Combos are Promising for High-Risk Smoldering Patients
ASH 2018: Poster Sessions at ASH Can Share Some Great Information!
A Tribute to Multiple Myeloma Advocate Eric Hansen
ASH 2018: Ninlaro as a Maintenance Therapy After Transplant
